On November 18, BeOne Medicines announced the official opening of its Shanghai Innovation Center. As the general contractor for the project, TIANS Group drew on its cutting-edge engineering design and technology integration capabilities to help bring this key R&D platform from blueprint to reality, laying a solid spatial and facility foundation for original innovation in biomedicine.
Located in Zhangjiang, Pudong, Shanghai, the BeOne Medicines Shanghai Innovation Center is a proprietary R&D center built from the ground up by the company. It covers a total gross floor area of 55,855 square meters and can accommodate more than 1,300 employees. The center brings together a diverse range of R&D capabilities, including discovery biology, medicinal chemistry, antibody engineering, ADC (antibody–drug conjugates), mRNA, protein degradation, and translational medicine. It is equipped with internationally advanced laboratories, SPF-grade animal facilities, and conventional animal facilities, with particular emphasis on building an AI-driven platform for antibody generation, discovery, and optimization, as well as a next-generation interdisciplinary ADC innovation platform.

Photo: BeOne Medicines Shanghai Innovation Center
Behind this high-standard R&D platform lie complex technical challenges arising from the close integration of multiple disciplines and systems. Throughout the project, the team took a forward-looking approach by introducing green and intelligent technologies and a lifecycle-wide BIM-based digital collaboration system. They performed refined design optimization for HVAC airflow organization, clean-environment control, and high-precision laboratory facilities, ensuring the successful completion of this top-tier drug R&D center defined by "high-end, intelligent, and international" standards. Thanks to outstanding delivery quality and a rigorous EHS management system, TIANS Group received BeOne Medicines' distinguished honors, including "Outstanding Partner" and "1.2 Million Safe Working Hours."

The opening of the BeOne Medicines Shanghai Innovation Center marks another example of TIANS Group empowering global innovative pharmaceutical companies and supporting the development of high-standard R&D facilities. To date, TIANS has provided integrated technical services covering concept planning, process design, and facility delivery to renowned biopharmaceutical companies at home and abroad, including BeOne Medicines, university biomedical technology transfer and commercialization centers, Junshi Biosciences, Hepalink, InnoCare Pharma, and GenScript Biotech—continuously helping to accelerate the translation of pharmaceutical innovations into industrial applications.